ArticleMolecular biology reports2026
Upregulation of ANRIL and H19 lncRNAs in bipolar disorder: a putative role for miR-339-5p in molecular pathogenesis.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsBipolar disorder (BD) is a highly heterogeneous and multifactorial condition that imposes substantial burdens on both individuals and society. Despite advances in understanding the neurobiology of BD, its precise etiology remains unclear. Long non-coding RNAs (lncRNAs), particularly H19 and ANRIL, have recently emerged as key regulators of inflammatory pathways and may contribute to the dysregulated immune responses observed in BD.
aimsThis study investigated the expression levels of H19 and ANRIL lncRNAs in individuals with BD and explored their potential role as biomarkers for the disorder. MATERIALS AND
methodsWe measured the expression levels of H19 and ANRIL in the peripheral blood of 90 patients with BD and 90 healthy controls using real-time PCR. Furthermore, receiver operating characteristic (ROC) curve analysis and correlation analysis were conducted to evaluate the association between gene expression and specific clinical features of BD. A computational study was conducted to investigate the binding sites of miRNAs on the H19 and ANRIL lncRNAs.
resultsThe expression levels of H19 and ANRIL were significantly higher in patients with BD compared to healthy controls. The area under the curve (AUC) values for H19 and ANRIL were 0.60 and 0.74, respectively. A computational study revealed that miR-339-5p is a common microRNA that may regulate H19 and ANRIL lncRNAs.
conclusionsGiven the role of miR-339-5p in inhibiting inflammation, the upregulation of H19 and ANRIL may contribute to the pathology of BD through the regulation of miR-339-5p. Moreover, peripheral expression levels of the lncRNA ANRIL may serve as potential biomarkers for BD. Importantly, these findings underscore the therapeutic promise of small RNA-based strategies-such as miRNA mimics or siRNA approaches-to restore immune balance and provide novel treatment options for BD.
Indexed as
Identifiers
42171908What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.